METHODS OF TREATING DISEASES ASSOCIATED WITH S1P1 RECEPTOR Russian patent published in 2024 - IPC A61K31/403 A61P17/00 A61P29/00 A61P37/02 

FIELD: medicine; pharmaceutics.

SUBSTANCE: group of inventions relates to methods of treating moderate to severe atopic dermatitis. Method of treating involves administering etrasimod or a pharmaceutically acceptable salt thereof to a patient in need thereof, determining a threshold value of the absolute lymphocyte count (ALC) in the patient and, if the ALC levels are below the threshold level, stopping the administration of etrasimod or a pharmaceutically acceptable salt thereof during the pause period. After cessation of etrasimod administration during the pause period, the administration of etrasimod or its pharmaceutically acceptable salt is continued during the continuation period. Threshold ALC value is less than 500/mm³ or from 0.2 × 10⁹ cells/l to 0.5 × 10⁹ cells/l, and etrasimod or its pharmaceutically acceptable salt is introduced in an amount equivalent to 1–5 mg. Also disclosed are versions of said method, comprising monitoring a patient for the presence of one or more infections after administration of etrasimod or a pharmaceutically acceptable salt thereof, wherein if one or more infections are detected, the introduction of etrasimod or its pharmaceutically acceptable salt is stopped during the pause period. Interval may vary from one day to four weeks.

EFFECT: group of inventions provides effective treatment of moderate to severe atopic dermatitis.

33 cl, 14 dwg, 1 tbl, 2 ex